Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study

In the CLARINET study, lanreotide Autogel (depot in USA) significantly prolonged progression-free survival (PFS) in patients with metastatic pancreatic/intestinal neuroendocrine tumours (NETs). We report long-term safety and additional efficacy data from the open-label extension (OLE). Patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Caplin, Martyn E, Pavel, Marianne, Ćwikła, Jarosław B, Phan, Alexandria T, Raderer, Markus, Sedláčková, Eva, Cadiot, Guillaume, Wolin, Edward M, Capdevila, Jaume, Wall, Lucy, Rindi, Guido, Langley, Alison, Martinez, Séverine, Gomez-Panzani, Edda, Ruszniewski, Philippe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bioscientifica Ltd 2016
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740728/
https://www.ncbi.nlm.nih.gov/pubmed/26743120
http://dx.doi.org/10.1530/ERC-15-0490

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4740728/
https://www.ncbi.nlm.nih.gov/pubmed/26743120
http://dx.doi.org/10.1530/ERC-15-0490

Ejemplares similares